💻 Technology · Tomorrow

Daniel Drucker (Joslin Diabetes Center / University of Toronto) wins Nobel Prize in Physiology or Medicine 2026 for foundational GLP-1 peptide research (announced October 5, 2026, confirmed via Nobel.org by October 6, 2026)

Miss ✦ AI-generated prediction Published on 3. October 2026 · Predicted for 5. October 2026 · Based on: Historical Cycle

Probability

25%

Kalshi rates Daniel Drucker at 26% (as of Oct 3, 2026), making him the top candidate on the largest US prediction market, ahead of James Fujimoto (12%) and Timothy Springer (9%). Drucker is a key architect behind GLP-1 agents (Ozempic/Wegovy class), which have globally transformed diabetes and obesity treatment and represent one of the most consequential therapeutic breakthroughs since insulin. Recent Nobel Medicine patterns (mRNA vaccines 2023, CRISPR 2020) favour transformative clinical-impact research. Co-laureates such as Jens Juul Holst (Copenhagen) or Svetlana Mojsov are plausible. Market odds reflect both candidacy strength and the persistently high residual uncertainty of Nobel selections.

Data basis for this prediction

Kalshi: 26 % für Daniel Drucker, Nobelpreis Medizin 2026 (Stand 3.10.2026)
Kalshi: James Fujimoto 12 %, Timothy Springer 9 % als nächste Kandidaten (Stand 3.10.2026)
The Scientist: 2026 Nobel Prize Preview — GLP-1-Kandidaten als Topfavoriten (September 2026)
richernews.com: Nobel Market Shortlist 2026 — Drucker als führender Kandidat (September 2026)

Verdict: Miss

Der Nobelpreis für Physiologie oder Medizin 2026 wurde am 5. Oktober 2026 an Karl Deisseroth (Stanford), Peter Hegemann (Humboldt-Universität Berlin) und Georg Nagel (Universität Würzburg) vergeben – für die Entdeckung lichtgesteuerter Ionenkanäle und die Entwicklung der Optogenetik. Daniel Drucker erhielt den Preis nicht. GLP-1-Forschung wurde nicht ausgezeichnet. Die Vorhersage lag trotz der starken Kalshi-Bewertung (26 %) vollständig daneben, da das Nobel-Komitee Optogenetik als Schwerpunkt wählte – ein Feld, das Hirnforschung und Neurobiologie revolutioniert hat und ebenfalls als langfristiger Nobelpreis-Kandidat galt. Quellen: https://www.nobelprize.org/prizes/medicine/2026/press-release/ und https://www.statnews.com/2026/10/05/nobel-prize-medicine-2026-winner-deisseroth-hegemann-nagel/

Related Predictions

💻 Technology ✦ AI

Applied Materials Inc. (NASDAQ: AMAT) beats Q4 FY2026 EPS consensus of $4.06 per share — earnings report November 12, 2026 after market close (confirmed by Applied Materials Investor Relations or Bloomberg by November 13, 2026, 10:00 AM ET)

Applied Materials has beaten the EPS consensus in all four of its last reported quarters, with an average earnings surprise of +3.5%. The company's own Q4 guidance is $3.82–$4.22 per share; consensus at $4.06 sits near the midpoint, reflecting classic conservative management framing. Revenue is estimated at $10.30B (+51% YoY) — TSMC and Samsung have not pulled back H2 2026 capex plans. No Polymarket market directly available; a 100% beat streak over 4 quarters with a positive guidance range implies 70–75% probability. Risk: supply chain delays or expanded US export controls on advanced chips could force a Q5 inventory build.

72%

Next Week · Predicted for 12. Nov 2026

💻 Technology ✦ AI

Palantir Technologies Inc. (NYSE: PLTR) closes above $185.00 per share on at least one trading day in November 2026 — confirmed by Nasdaq or Bloomberg by December 1, 2026

PLTR closed at $175.40 on November 4, 2026 (after-hours: $170.88, -2.58%; intraday high: $176.54; 52-week high: $212.94). Palantir clearly beat Q3-FY2026 EPS consensus: total revenue $2.313B, US Commercial revenue +148% YoY to $984M. The $185 threshold is +5.5% above the closing price or +8.3% above after-hours levels. Typical post-earnings 'sell the news' may weigh short-term, but the 52-week high of $212.94 confirms the level is reachable. NVIDIA earnings on November 18, 2026 could serve as a sector-wide catalyst. No direct Polymarket equivalent; own estimate: ~42%.

42%

Next Month · Predicted for 30. Nov 2026

💻 Technology ✦ AI

Cerebras Systems (NASDAQ: CBRS) closes below $100.00 per share on November 10, 2026 (confirmed by Nasdaq or Bloomberg by November 11, 2026)

CBRS trades at $109.18 (October 30, 2026) — already 61% below its all-time high of $279.72. The final and largest lockup expiration is scheduled for November 10, 2026: approximately 19.4 million shares are unlocked (of three tranches of 19.4M each). Prior lockup tranches have consistently weighed on the stock. Insiders have sold ~$394.6M in shares since the May 2026 IPO — zero insider purchases. A Culper Research short-seller report has triggered multiple investigations. A close below $100 requires a ~8.4% decline — plausible given the expected supply pressure on expiration day.

62%

Next Week · Predicted for 10. Nov 2026